共 50 条
- [1] Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 VaccinationONCOLOGIST, 2022, 27 (11): : E916 - E916Sriwijitalai, WonWiwanitkit, Viroj
- [2] Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignanciesCANCER CELL, 2021, 39 (08) : 1031 - 1033Greenberger, Lee M.Saltzman, Larry A.Senefeld, Jonathon W.Johnson, Patrick W.DeGennaro, Louis J.Nichols, Gwen L.
- [3] Serological response to SARS-CoV-2 vaccination in patients with immunobullous diseasesJEADV CLINICAL PRACTICE, 2024, 3 (05): : 1686 - 1689Levian, B.Tukaj, S.Woodley, D. T.Kasperkiewicz, M.
- [4] Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic DiseasesBLOOD, 2020, 136Cattaneo, ChiaraCancelli, ValeriaPagani, ChiaraTucci, AlessandraRossi, GiuseppeImberti, LuisaSottini, AlessandraDobbs, KerryShaw, ElanaNotarangelo, Luigi D.Cohen, JeffreyBurbelo, Peter
- [5] Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 VaccinationONCOLOGIST, 2022, 27 (04): : E357 - E361Guven, Deniz C.Sahin, Taha K.Akin, SerkanUckun, Fatih M.
- [6] Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic PatientsFRONTIERS IN IMMUNOLOGY, 2022, 13Fattizzo, BrunoBortolotti, MartaRampi, NicoloCavallaro, FrancescaGiannotta, Juri AlessandroBucelli, CristinaCassin, RamonaDa Via, Matteo ClaudioGalassi, GiuliaNoto, AlessandroPettine, LoredanaRossi, Francesca GaiaSciume, MariaritaCeriotti, FerruccioConsonni, DarioBarcellini, WilmaBaldini, Luca
- [7] Antibody Response to SARS-CoV-2 mRNA Vaccination in Patients with Cystic FibrosisAMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205Lee, L.Milla, C. E.Kim, P. S.
- [8] Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseasesANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (10) : 1357 - +Spiera, RobertJinich, SarahJannat-Khah, Deanna
- [9] Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignanciesBLOOD ADVANCES, 2022, 6 (03) : 774 - 784Jimenez, MoraimaRoldan, ElisaFernandez-Naval, CandelaVillacampa, GuillermoMartinez-Gallo, MonicaMedina-Gil, DanielPeralta-Garzon, SorayaPujadas, GemmaHernandez, CristinaPages, CarlotaGironella, MercedesFox, LauraOrti, GuillermoBarba, PerePumarola, TomasCabirta, AlbaCatala, EvaValentin, MercedesMarin-Niebla, AnaOrfao, AlbertoGonzalez, MarcosCampins, MagdaRuiz-Camps, IsabelValcarcel, DavidBosch, FrancescHernandez, ManuelCrespo, MartaEsperalba, JulianaAbrisqueta, Pau
- [10] Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignanciesBLOOD CANCER JOURNAL, 2021, 11 (08)Malard, FlorentGaugler, BeatriceGozlan, JoelBouquet, LucieFofana, DjenebaSiblany, LamaEshagh, DeborahAdotevi, OlivierLaheurte, CarolineRicard, LaureDulery, RemyStocker, Nicolasvan de Wyngaert, ZoeGenthon, AlexisBanet, AnneMemoli, MaraIkhlef, SouhilaSestilli, SimonaVekhof, AnneBrissot, EoliaMarjanovic, ZoraChantran, YannickCuervo, NancyBallot, EricMorand-Joubert, LaurenceMohty, Mohamad